曲妥珠单抗联合帕妥珠单抗治疗经治晚期HER2外显子20突变非小细胞肺癌
在药物再发现方案(DRUP)中,HER2外显子20突变阳性晚期经治非小细胞肺癌患者接受曲妥珠单抗联合帕妥珠单抗每3周静脉给药。24例可评估患者中临床获益9例(38%),客观缓解率8.3%(2例部分缓解),7例疾病稳定≥16周。中位随访13个月,中位无进展生存期4个月(95%CI 3-6),中位总生存期10个月(95%CI 4-未达到)。
要点
- 24例可评估患者中临床获益9例(38%),客观缓解率8.3%,部分缓解2例,疾病稳定≥16周7例。
- 中位无进展生存期4个月(95%CI 3-6),中位总生存期10个月(95%CI 4-未达到)。
- 最常见的HER2突变为p.Y772_A775dup(71%,n=20),未观察到意外毒性。
核心结论
- 尽管研究达到了主要终点,曲妥珠单抗联合帕妥珠单抗在经重度治疗的HER2外显子20突变阳性非小细胞肺癌患者中仅对一部分患者有边缘活性。
研究设计与样本
- 药物再发现方案(DRUP)中的队列研究,入组经治晚期HER2外显子20突变阳性非小细胞肺癌患者,要求有可测量病灶(RECIST v1.1)。
- 采用类Simon两阶段设计,第一阶段8例,若第一阶段至少1例临床获益则第二阶段最多入组24例;共24例可评估患者于2017年5月至2020年8月入组并治疗。
- 治疗为曲妥珠单抗联合帕妥珠单抗每3周静脉给药;主要终点为临床获益(客观缓解或疾病稳定≥16周)。
- 基线时获取活检用于生物标志物分析,包括全基因组测序。
主要发现
- 24例可评估患者中临床获益9例(38%),包括客观缓解率8.3%(2例部分缓解)和7例疾病稳定≥16周。
- 最常见的HER2突变为p.Y772_A775dup(71%,n=20)。
- 中位随访13个月,中位无进展生存期4个月(95%CI 3-6),中位总生存期10个月(95%CI 4-未达到)。
- 全基因组测序数据(67%患者可获得)在所有病例中确认了入组突变。
- 未观察到意外毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In 1-3% of non-small cell lung cancer (NSCLC) human epidermal growth factor 2 (HER2) mutations are identified as a genomic driver. Nevertheless, no HER2-targeted treatment is approved for NSCLC. In the Drug Rediscovery Protocol (DRUP), patients are treated with off-label drugs based on their molecular profile. Here, we present the results of the cohort 'trastuzumab/pertuzumab for HER2 exon20 mutation positive (HER2m+) NSCLC'. METHODS: Patients with treatment refractory, advanced HER2m+ NSCLC with measurable disease (RECISTv1.1) were eligible. Treatment with intravenous trastuzumab combined with pertuzumab every 3 weeks was administered. The primary end-point was clinical benefit (CB: either objective response or stable disease ≥ 16 weeks). Patients were enrolled using a Simon-like 2-stage design, with 8 patients in stage 1 and up to 24 patients in stage 2 if at least 1 patient had CB in stage 1. At baseline, a biopsy for biomarker analysis, including whole genome sequencing, was obtained. RESULTS: Twenty-four evaluable patients were enrolled and treated between May 2017 and August 2020. CB was observed in 9 patients (38%); including an objective response rate of 8.3% (2 patients had a partial response) and 7 patients with stable disease ≥ 16 weeks. The most frequently observed HER2 mutation was p.Y772_A775dup (71%, n = 20). Median follow-up was 13 months, median progression-free survival and overall survival 4 (95% CI 3-6) and 10 months (95% CI 4 - not reached), respectively. Whole genome sequencing data (available for 67% of patients) confirmed the inclusion mutation in all cases. No unexpected toxicity was observed. CONCLUSION: Despite the fact that the study did meet its primary end-point, trastuzumab/pertuzumab was only marginally active in a subset of patients with heavily pre-treated HER2m+ NSCLC.
引用
- van Berge Henegouwen JM, Jebbink M, Hoes LR, et al. Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer. Eur J Cancer. 2022. PMID: 35716537. doi:10.1016/j.ejca.2022.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。